Stenocare Price To Sales vs. Beta

STENO Stock  DKK 2.04  0.14  7.37%   
Based on the measurements of profitability obtained from Stenocare's financial statements, Stenocare AS may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Stenocare's ability to earn profits and add value for shareholders.
For Stenocare profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Stenocare to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Stenocare AS utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Stenocare's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Stenocare AS over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
Please note, there is a significant difference between Stenocare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Stenocare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stenocare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Stenocare AS Beta vs. Price To Sales Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Stenocare's current stock value. Our valuation model uses many indicators to compare Stenocare value to that of its competitors to determine the firm's financial worth.
Stenocare AS is rated below average in price to sales category among its peers. It is rated below average in beta category among its peers . The ratio of Price To Sales to Beta for Stenocare AS is about  635.24 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Stenocare by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Stenocare's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Stenocare Beta vs. Price To Sales

Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

Stenocare

P/S

 = 

MV Per Share

Revenue Per Share

 = 
67.34 X
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.

Stenocare

Beta

 = 

Covariance

Variance

 = 
0.11
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.

Stenocare Beta Comparison

Stenocare is rated below average in beta category among its peers.

Beta Analysis

As returns on the market increase, Stenocare's returns are expected to increase less than the market. However, during the bear market, the loss of holding Stenocare is expected to be smaller as well.

Stenocare Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Stenocare, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Stenocare will eventually generate negative long term returns. The profitability progress is the general direction of Stenocare's change in net profit over the period of time. It can combine multiple indicators of Stenocare, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Stenocare AS cultivates, produces, imports, sells, and distributes prescription-based medical cannabis products in the Danish and European markets. The company was founded in 2017 and is headquartered in Allerd, Denmark. STENOCARE is traded on Copenhagen Stock Exchange in Denmark.

Stenocare Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Stenocare. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Stenocare position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Stenocare's important profitability drivers and their relationship over time.

Use Stenocare in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Stenocare position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Stenocare will appreciate offsetting losses from the drop in the long position's value.

Stenocare Pair Trading

Stenocare AS Pair Trading Analysis

The ability to find closely correlated positions to Stenocare could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Stenocare when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Stenocare - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Stenocare AS to buy it.
The correlation of Stenocare is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Stenocare moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Stenocare AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Stenocare can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Stenocare position

In addition to having Stenocare in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Marketing Thematic Idea Now

Marketing
Marketing Theme
Companies providing marketing and public relation (PR) services as well as news and media distribution. The Marketing theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Marketing Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Stenocare Stock

To fully project Stenocare's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Stenocare AS at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Stenocare's income statement, its balance sheet, and the statement of cash flows.
Potential Stenocare investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Stenocare investors may work on each financial statement separately, they are all related. The changes in Stenocare's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Stenocare's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.